Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Delayed Diagnosis of Indolent Systemic Mastocytosis as the Cause of Unexplained Skin Rash: A Case Report

Delayed Diagnosis of Indolent Systemic Mastocytosis as the Cause of Unexplained Skin Rash: A Case... Mastocytosis is a heterogeneous group of disorders in which mast cells exhibit clonal proliferation that infiltrates one or more organs. In cutaneous mastocytosis, the mast cells infiltrate the skin only, whereas systemic mastocytosis is diagnosed when at least one extra-cutaneous site is involved, with or without the skin being affected. Given the rarity of mastocytosis and the fact that skin rash can be a manifestation of different conditions and many clinicians are not familiar with this disorder, an accurate diagnosis may be delayed. We report a delayed diagnosis of indolent systemic mastocytosis in a 40-year-old gentleman who had been complaining of an unexplained skin rash for 6 years. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Case Reports in Oncology Karger

Delayed Diagnosis of Indolent Systemic Mastocytosis as the Cause of Unexplained Skin Rash: A Case Report

Download PDF
7 pages

Loading next page...
 
/lp/karger/delayed-diagnosis-of-indolent-systemic-mastocytosis-as-the-cause-of-odoUzjZ9fY
Publisher
Karger
Copyright
© 2023 The Author(s). Published by S. Karger AG, Basel
eISSN
1662-6575
DOI
10.1159/000529347
Publisher site
See Article on Publisher Site

Abstract

Mastocytosis is a heterogeneous group of disorders in which mast cells exhibit clonal proliferation that infiltrates one or more organs. In cutaneous mastocytosis, the mast cells infiltrate the skin only, whereas systemic mastocytosis is diagnosed when at least one extra-cutaneous site is involved, with or without the skin being affected. Given the rarity of mastocytosis and the fact that skin rash can be a manifestation of different conditions and many clinicians are not familiar with this disorder, an accurate diagnosis may be delayed. We report a delayed diagnosis of indolent systemic mastocytosis in a 40-year-old gentleman who had been complaining of an unexplained skin rash for 6 years.

Journal

Case Reports in Oncology – Karger

Published: Jan 1, 2023

Keywords: Mastocytosis; Indolent systemic mastocytosis; Skin rash; Urticaria pigmentosa

References

  • Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
    Valent, P; Akin, C; Metcalfe, DD
  • Acute myeloid leukemia with inv(16)(p13q22) associated with hidden systemic mastocytosis: case report and review of literature
    Hilmi, FAI; Al-Sabbagh, A; Soliman, DS; Sabah, HA; Ismail, OM; Yassin, M
  • Epidemiology, prognosis, and risk factors in mastocytosis
    Brockow, K
  • Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification
    Trizuljak, J; Sperr, WR; Nekvindová, L; Elberink, HO; Gleixner, KV; Gorska, A
  • Highly aggressive CD4-positive mast cell leukaemia (leukaemic variant) associated with isolated trisomy 19 and hemophagocytosis by neoplastic mast cells: a case report with challenging experience and review
    Soliman, DS; Al-Sabbagh, A; Ibrahim, F; Gameil, A; Yassin, M; El-Omri, H
  • Challenging diagnosis of indolent systemic mastocytosis isolated to the GI tract
    Horton, L; Al-Kourainy, N; Kabbani, D; Bishop, CR
  • Indolent systemic mastocytosis: a case and review of the current available treatment options
    Lee, Y; Wood, P; Soyer, HP
  • Delayed diagnosis of adult indolent systemic mastocytosis
    Mikkelsen, CS; Nybo, A; Arvesen, KB; Holk-Poulsen, J
  • Mastocytosis: state of the art
    Horny, HP; Sotlar, K; Valent, P
  • Clinical and histopathological aspects of cutaneous mastocytosis
    Wolff, K; Komar, M; Petzelbauer, P
  • A rare case of systemic mastocytosis with associated hematologic neoplasm (SM-AHN) involving chronic myeloid leukemia: a case report and literature review
    Ibrahim, FA; Abdulla, MAJ; Soliman, D; Al Sabbagh, A; Nawaz, Z; Akiki, SJ
  • International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers
    Biggi, A; Gallamini, A; Chauvie, S; Hutchings, M; Kostakoglu, L; Gregianin, M
  • How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?
    Hutchings, M
  • FDG-PET/CT findings in systemic mastocytosis: a French multicentre study
    Djelbani-Ahmed, S; Chandesris, MO; Mekinian, A; Canioni, D; Brouzes, C; Hanssens, K
  • Aggressive systemic mastocytosis with diffuse bone marrow 18F-FDG uptake
    Koukalová, R; Vašina, J; Štika, J; Doubek, M; Szturz, P